Pharma Moves From ‘Denial’ To ‘Acceptance’ Of Post-Grant Patent Challenges
Executive Summary
Cubist attorney says inter partes review proceeding could push companies to pursue different types of innovations while Merck attorney sees it as another litigation tool.